Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.

IF 1.3 Q4 RESPIRATORY SYSTEM
F Charles, Y D Lin, J Greig, S Gurra, R Morikawa, S M Graham, A Maha
{"title":"Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.","authors":"F Charles, Y D Lin, J Greig, S Gurra, R Morikawa, S M Graham, A Maha","doi":"10.5588/pha.24.0004","DOIUrl":null,"url":null,"abstract":"<p><strong>Setting: </strong>Multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) is now endemic in the National Capital District (NCD), Papua New Guinea. Loss to follow-up (LTFU) is a challenge.</p><p><strong>Objective: </strong>To evaluate and identify risk factors for LTFU, including pre-treatment LTFU, in adults with MDR/RR-TB at Port Moresby General Hospital (PMGH).</p><p><strong>Design: </strong>A retrospective analysis of treatment initiation in adults diagnosed with MDR/RR-TB (2018-2022) and outcomes for a cohort treated for MDR/RR-TB (2014-2019). We assessed the factors associated with LTFU using multivariate logistic regression.</p><p><strong>Results: </strong>Of 95 patients diagnosed with MDR/RR-TB at PMGH from 2018 to 2022, 21 (22%) were lost to follow-up before treatment. Of the 658 adults who initiated treatment for MDR/RR-TB at PMGH from 2014 to 2019, 161 (24%) were lost to follow-up during treatment. A higher proportion of patients on injectable-containing long regimens (110/404, 27%) were lost to follow-up than those on the all-oral regimen containing bedaquiline (13/66, 12%). Treatment loss to follow-up was associated with age (35-54 years age group: aOR 0.49, 95% CI 0.32-0.77; 55-75 years age group: aOR 0.42, 95% CI 0.19-0.90; compared to the 15-34 years age group), residence outside of NCD (aOR 1.79, 95% CI 1.04-3.06), and year of treatment initiation.</p><p><strong>Conclusion: </strong>Pre-treatment LTFU requires programmatic focus. Shorter oral regimens and decentralised services may address the reasons for higher LTFU in younger people and people living outside NCD.</p>","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":"14 3","pages":"85-90"},"PeriodicalIF":1.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373746/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.24.0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Setting: Multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) is now endemic in the National Capital District (NCD), Papua New Guinea. Loss to follow-up (LTFU) is a challenge.

Objective: To evaluate and identify risk factors for LTFU, including pre-treatment LTFU, in adults with MDR/RR-TB at Port Moresby General Hospital (PMGH).

Design: A retrospective analysis of treatment initiation in adults diagnosed with MDR/RR-TB (2018-2022) and outcomes for a cohort treated for MDR/RR-TB (2014-2019). We assessed the factors associated with LTFU using multivariate logistic regression.

Results: Of 95 patients diagnosed with MDR/RR-TB at PMGH from 2018 to 2022, 21 (22%) were lost to follow-up before treatment. Of the 658 adults who initiated treatment for MDR/RR-TB at PMGH from 2014 to 2019, 161 (24%) were lost to follow-up during treatment. A higher proportion of patients on injectable-containing long regimens (110/404, 27%) were lost to follow-up than those on the all-oral regimen containing bedaquiline (13/66, 12%). Treatment loss to follow-up was associated with age (35-54 years age group: aOR 0.49, 95% CI 0.32-0.77; 55-75 years age group: aOR 0.42, 95% CI 0.19-0.90; compared to the 15-34 years age group), residence outside of NCD (aOR 1.79, 95% CI 1.04-3.06), and year of treatment initiation.

Conclusion: Pre-treatment LTFU requires programmatic focus. Shorter oral regimens and decentralised services may address the reasons for higher LTFU in younger people and people living outside NCD.

巴布亚新几内亚成人耐药结核病患者失去随访机会。
背景:巴布亚新几内亚国家首都区(NCD)目前流行耐多药/耐利福平结核病(MDR/RR-TB)。失去随访(LTFU)是一项挑战:评估并确定莫尔兹比港总医院(PMGH)MDR/RR-TB成人患者LTFU(包括治疗前LTFU)的风险因素:对确诊为MDR/RR-TB成人患者的治疗启动情况(2018-2022年)和MDR/RR-TB治疗队列的治疗结果(2014-2019年)进行回顾性分析。我们使用多变量逻辑回归评估了与LTFU相关的因素:2018年至2022年在PMGH确诊为MDR/RR-TB的95名患者中,有21人(22%)在治疗前失去随访。2014年至2019年在PMGH接受MDR/RR-TB治疗的658名成人中,有161人(24%)在治疗期间失去了随访。与使用含有贝达喹啉的全口服治疗方案的患者(13/66,12%)相比,使用含有注射剂的长效治疗方案的患者(110/404,27%)失去随访的比例更高。随访治疗损失与年龄(35-54 岁年龄组:aOR 0.49,95% CI 0.32-0.77;55-75 岁年龄组:aOR 0.42,95% CI 0.19-0.90;与 15-34 岁年龄组相比)、NCD 以外的居住地(aOR 1.79,95% CI 1.04-3.06)和开始治疗的年份有关:结论:治疗前LTFU需要重点关注。较短的口服治疗方案和分散的服务可解决年轻人和居住在 NCD 以外地区的人群中治疗时间较长的原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Public Health Action
Public Health Action RESPIRATORY SYSTEM-
自引率
0.00%
发文量
29
期刊介绍: Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信